CereSpir™ Incorporated, a biotechnology company firm advancing CSP-1103, which is a first-in-class modulator of the innate immune system of the brain to address treatment for Alzheimer’s disease, recently announced that Sophie Egholm has been appointed as Chief Operating Officer of the company. Egholm is a pharmacologist and medicinal chemist who has spent her whole career in the pharmaceutical industry as a holder of senior management positions, thanks to her excellent track record in Finance, Business and Operations Management with top experience in clinical trials specifically designed for Alzheimer’s.
CereSpir™ is advancing CSP-1103, an orally delivered tablet with high potential to treat Mild Cognitive Impairment (MCI) thanks to targeting the stage of symptomatic disease before the onset of dementia. CSP-1103 is now under Phase 2 testing in individuals with MCI and CereSpir’s phase 3 program is being finalized based on input from the United States Food Drug Administration, European Medicines Agency and Japanese Pharmaceuticals and Medical Device Agency (PMDA). The firm is also planning an orphan drug development program to be developed in parallel for Batten disease.
Egholm’s career includes being the both the Head of Operations and President of the Clinical Trials Business Unit at Cogstate Ltd, Associate Director, Strategic Alliances and Worldwide Business Development at Pfizer. She was also the Global Marketing Manager at UCB BIOPRODUCTS in Belgium. Egholm received her Master’s degree in Engineering from the Free University of Brussels and an Advanced Master’s in Medical Chemistry and Pharmacology from Lille Pharmacy University in Belgium.
“I am delighted to welcome Sophie as Chief Operating Officer, a role for which she is superbly qualified. Her considerable breadth of experience and extraordinary talents will be invaluable to help grow the company and achieve our business objectives,” said Daniel Chain, PhD, Chief Executive Officer and CereSpir’s President.
“I am excited to join CereSpir and very pleased to have this opportunity to help the company succeed in it’s critically important mission that could benefit of millions of people affected by Alzheimer’s disease and other neurodegenerative conditions,” added Sophie Egholm.